AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03321903 — intervention group
Intervention type: DEVICE
Intervention: Carlo Erba Ink Injection
Description: Carlo Erba India ink is used in this study as a paramagnetic oxygen sensor that is injected into tissue, and which, when measured using EPR Oximetry, can provide sensitive, repeated, and direct measurements of tissue oxygen. Each study participant will receive at least one ink injection of 20-50µL of Carlo Erba India Ink. The ink injection will occur within 5mm of the body surface (i.e., skin or mucosa), and may be injected into tumor, postsurgical field of radiation, and/or adjacent normal tissue. Carlo Erba Ink is an aqueous suspension composed of charcoal powder, water for injection, and a suspending agent. Carlo Erba is the name of the manufacturer that supplies the charcoal.
Study NCT03321903 — intervention group
Intervention type: OTHER
Intervention: EPR Oximetry Measurement
Description: An oximetry measurement visit consists of \~ 30 minutes of continuous scans of tissue oxygen in vivo, using an oxygen sensor (i.e., India ink) injected into the tumor that is noninvasively scanned using EPR oximetry. Scans, converted into measurements of pO2, characterize the current tumor oxygen level at: (1) 'steady state' (while breathing room air), 2) response to hyperoxygenation therapy (inhaling oxygen-enriched air for 10 min), and 3) response to resuming inhaling room air. EPR measurements are repeated noninvasively throughout radiation or chemotherapy, to examine changes. The minimum number of visits depends on the patient's cohort; all may have additional measurements. If the ink injection is not surgically removed, EPR oximetry measurements can be repeated indefinitely.
Study NCT01806025 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT01166958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
Study NCT01166958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
Study NCT04690803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: air cooling
Description: intervention is adding air-cooling to treatment
Study NCT04503668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
Study NCT04503668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 8 mg IV or 16 mg by mouth on day 1 pre-chemotherapy; then 8 mg by mouth twice a day on days 2-4 of chemotherapy
Study NCT04503668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 mg IV on day 1 pre-chemotherapy
Study NCT04503668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg IV on day 1 pre-chemotherapy
Study NCT04503668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurokinin-1 Receptor Antagonist (NK1-RA)
Description: 150 mg IV on day 1 pre-chemotherapy
Study NCT04503668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 5 mg by mouth on days 1-4 of chemotherapy (taken at night)
Study NCT04378413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise for low back pain
Study NCT02599324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Ibrutinib administered orally once daily with 8 ounces (approximately 240 mL) of water.
Study NCT04503668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compazine
Description: 5-10 mg by mouth, available as needed, every 6 hours, days 1-5
Study NCT04503668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compazine
Description: 5-10 mg by mouth, available as needed, every 6 hours, days 1-5
Study NCT02599324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus 10 mg tablets should be taken orally once daily at the same time every day, either consistently with food or consistently without food. Four (4) x 2.5 mg tablets or two (2) x 5.0 mg tablets may be substituted if 10 mg tablet strength is not available.
Study NCT02813668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention Training Program
Description: Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 5% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
Study NCT04393467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tSMS
Description: tSMS delivered on bilateral motor cortex
Study NCT02599324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel should be administered as a 60-minute (±10 minutes) infusion. Paclitaxel should be given at a dose level of 80 mg/m\^2, once weekly, in continual 3 weekly cycles.
Study NCT02599324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel administered as a 60 minute infusion (±10 minutes) at a dose level of 60 - 75 mg/m\^2 (according to local institutional standard of care), given continually in 21-day cycles.
Study NCT02599324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cetuximab 400 mg/m\^2 administered as a 120-minute IV infusion. The recommended subsequent weekly dose (all other infusions) is 250 mg/m\^2 infused over 60 minutes.
Study NCT02599324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab 200 mg intravenous (IV) every 3 weeks.
Study NCT03485404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylcobalamin
Description: methylcobalamin tablets, 0.5mg/tablet, 3 tablets/day.
Study NCT03485404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: folic acid tablets, 5mg/tablet, 1 tablet/day
Study NCT03485404 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for methylcobalamin
Description: orange tablets that looks exactly like methylcobalamin
Study NCT03485404 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for folic acid
Description: yellow tablets that looks exactly like folic acid
Study NCT03485404 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non-cardiac surgery
Description: patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention
Study NCT03485404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-cardiac surgery
Description: patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention
Study NCT03485404 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NPB test
Description: participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
Study NCT03485404 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: NPB test
Description: participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
Study NCT03485404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NPB test
Description: participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
Study NCT04383665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN DBS 10Hz
Description: Stimulation of existing DBS device at 100Hz, with other parameters at baseline
Study NCT04383665 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STN DBS 130Hz
Description: Stimulation of existing DBS device at 130Hz, with other parameters at baseline
Study NCT04383665 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: STN DBS off
Description: Existing DBS device turned off
Study NCT00671190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 1 mg, tablets, orally once daily for up to 5 days
Study NCT00671190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 2 mg, tablets, orally once daily for up to 5 days
Study NCT00671190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 4 mg, tablets, orally once daily for up to 5 days
Study NCT00671190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally once daily for up to 5 days
Study NCT00671190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets, orally once daily for up to 5 days
Study NCT04453618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE-SYHA1402 100mg
Description: in either a fasted state or with a meal
Study NCT04453618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1402-25mg
Description: SYHA1402 25mg, oral tablets
Study NCT04453618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-25mg
Description: Matching placebo tablets
Study NCT04453618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1402-50mg
Description: SYHA1402 50mg, oral tablets
Study NCT04453618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-50mg
Description: Matching placebo tablets
Study NCT04453618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1402-150mg
Description: SYHA1402 150mg, oral tablets
Study NCT04453618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-150mg
Description: Matching placebo tablets
Study NCT02685449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin glulisine
Description: A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
Study NCT02685449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
Study NCT02685449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin aspart
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Study NCT02685449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin aspart
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Study NCT02685449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin lispro
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Study NCT02685449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro
Description: A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
Study NCT00957060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE (HOE490)
Description: Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
Study NCT00957060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SITAGLIPTIN
Description: Pharmaceutical form: 100 mg tablets Route of administration: oral
Study NCT01308528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium enoxaparin
Description: 40 mg/mL
Study NCT01308528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Enoxaparin clexane
Description: clexane 40 mg/ 0,4 mL
Study NCT02477540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellgram-CLI
Description: Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip~Main ingredient: Autologous bone marrow-derived mesenchymal stem cells~Dosage: 50,000,000 cells/10ml, 2-time injection~Storage: An airtight container, 20\~25℃~Injection Method: Intramuscular
Study NCT03530189 — intervention group
Intervention type: DRUG
Intervention: 10% dextrose
Description: After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
Study NCT03530189 — intervention group
Intervention type: DRUG
Intervention: bolus of dextrose, reducing the glucose infusion, insulin
Description: Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200-300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion.
Study NCT01156012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2345
Description: One drop of T2345
Study NCT01156012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin
Description: One drop
Study NCT01662128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Xeloda as Adjuvant Therapy
Study NCT01562379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Soy Blend (WSB++)
Description: A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.
Study NCT01562379 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chickpea based complementary food supplement
Description: A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
Study NCT04393467 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tSMS
Description: sham tSMS delivered on bilateral motor cortex by a non-magnetic steel cylinder, with same size, weight and appearance of the magnet used for real tSMS
Study NCT05034315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole egg consumption
Description: The participants in the whole egg group consumed two whole eggs immediately after exercise.
Study NCT04151628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lithotripsy
Description: Deliver Lithotripsy to the target vessel prior to placing a coronary stent
Study NCT04362371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ainara
Description: 1 g at each administration
Study NCT01294943 — intervention group
Intervention type: DEVICE
Intervention: Tongue cleaner
Description: Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
Study NCT00353431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novorapid ®, Novo Nordisk, Denmark
Description: Comparison of a sliding scale with an intensive s.c. scale
Study NCT00353431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novorapid ®, Novo Nordisk, Denmark
Description: Comparison of a sliding scale with an intensive s.c. scale
Study NCT04287569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Record during endoscopy of video-endoscopy sequences and reflectance
Description: Record of video-endoscopy sequences and reflectance, during endoscopy with biopsy.
Study NCT03271073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
Study NCT04618042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX06
Description: FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
Study NCT04618042 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of FX06
Description: Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
Study NCT03661788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
Study NCT03661788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: 14-day treatment interval: first week one placebo pill, second week two placebo pills
Study NCT01866423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: orteronel
Description: Given PO
Study NCT01866423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03252093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: Subcutaneous injection of 200 mcg/kg/day
Study NCT03252093 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Angiotensin-(1-7)
Description: Subcutaneous injection of Placebo
Study NCT00940095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan 5 m/h
Description: Continuous intravenous infusion of clazosentan (5 mg/h)
Study NCT00940095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan 15 mg/h
Description: Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)
Study NCT00940095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous intravenous infusion of placebo-matching clazosentan
Study NCT03818347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxyhydrogen generator (AMS-H-03)
Description: Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively. The patients inhale 3 hours each day through a cannula or mask, and persist for long term
Study NCT03818347 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: analogue machine
Description: This machine has the same apperance and gas condition
Study NCT00712569 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
Study NCT00712569 — intervention group
Intervention type: BEHAVIORAL
Intervention: audio recordings , questionnaires
Description: Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not.
Study NCT00712569 — intervention group
Intervention type: BEHAVIORAL
Intervention: audio recorded questionnaires
Description: Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
Study NCT04072679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+IBI305
Description: It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
Study NCT01110837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen
Description: Allergen nasal challenge
Study NCT01110837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo challenge
Description: Placebo nasal challenge
Study NCT02593812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping training
Description: Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.